hydroxychloroquine has been researched along with Brucellosis in 4 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Brucellosis: Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies have shown the effect of hydroxychloroquine in the treatment and prevention of recurrence of brucellosis." | 9.51 | Combination of doxycycline, streptomycin and hydroxychloroquine for short-course treatment of brucellosis: a single-blind randomized clinical trial. ( Emami, K; Hashmi, SH; Majzoobi, MM; Soltanian, AR, 2022) |
| "Can brucellosis-related biochemical and immunological parameters be used as diagnostic and treatment indicators? The goal of this project was to look at biochemical parameters, trace elements, and inflammatory factors in the acute and chronic stages of brucellosis after treatment with streptomycin and hydroxychloroquine-loaded solid lipid nanoparticles (STR-HCQ-SLN)." | 8.31 | Co-delivery of streptomycin and hydroxychloroquine by labeled solid lipid nanoparticles to treat brucellosis: an animal study. ( Arabestani, MR; Hosseini, SM; Kalhori, F; Moez, NM; Shokoohizadeh, L, 2023) |
| "Brucellosis is associated with a high recurrence rate and requires more than one course of standard treatment; therefore, more research is required to find more effective treatments that lead to prompt recovery, and reduce the relapse of disease." | 6.87 | Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: a single-blind, randomized clinical trial. ( Ghasemi Basir, HR; Hashemi, SH; Keramat, F; Majzoobi, MM; Mamani, M; Poorolajal, J, 2018) |
| "Previous studies have shown the effect of hydroxychloroquine in the treatment and prevention of recurrence of brucellosis." | 5.51 | Combination of doxycycline, streptomycin and hydroxychloroquine for short-course treatment of brucellosis: a single-blind randomized clinical trial. ( Emami, K; Hashmi, SH; Majzoobi, MM; Soltanian, AR, 2022) |
| "Can brucellosis-related biochemical and immunological parameters be used as diagnostic and treatment indicators? The goal of this project was to look at biochemical parameters, trace elements, and inflammatory factors in the acute and chronic stages of brucellosis after treatment with streptomycin and hydroxychloroquine-loaded solid lipid nanoparticles (STR-HCQ-SLN)." | 4.31 | Co-delivery of streptomycin and hydroxychloroquine by labeled solid lipid nanoparticles to treat brucellosis: an animal study. ( Arabestani, MR; Hosseini, SM; Kalhori, F; Moez, NM; Shokoohizadeh, L, 2023) |
| "Brucellosis is associated with a high recurrence rate and requires more than one course of standard treatment; therefore, more research is required to find more effective treatments that lead to prompt recovery, and reduce the relapse of disease." | 2.87 | Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: a single-blind, randomized clinical trial. ( Ghasemi Basir, HR; Hashemi, SH; Keramat, F; Majzoobi, MM; Mamani, M; Poorolajal, J, 2018) |
| "Brucellosis is considered one of the most important infectious diseases affecting any tissue and organ in the human body." | 1.91 | Use of the quantum dot-labeled solid lipid nanoparticles for delivery of streptomycin and hydroxychloroquine: A new therapeutic approach for treatment of intracellular Brucella abortus infection. ( Arabestani, MR; Chegini, Z; Hosseini, SM; Karimitabar, Z; Moez, NM; Shokoohizadeh, L, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Majzoobi, MM | 2 |
| Hashmi, SH | 1 |
| Emami, K | 1 |
| Soltanian, AR | 1 |
| Karimitabar, Z | 2 |
| Chegini, Z | 2 |
| Shokoohizadeh, L | 3 |
| Moez, NM | 3 |
| Arabestani, MR | 3 |
| Hosseini, SM | 3 |
| Kalhori, F | 1 |
| Hashemi, SH | 1 |
| Mamani, M | 1 |
| Keramat, F | 1 |
| Poorolajal, J | 1 |
| Ghasemi Basir, HR | 1 |
2 trials available for hydroxychloroquine and Brucellosis
| Article | Year |
|---|---|
Combination of doxycycline, streptomycin and hydroxychloroquine for short-course treatment of brucellosis: a single-blind randomized clinical trial.
Topics: Anti-Bacterial Agents; Brucellosis; Doxycycline; Drug Therapy, Combination; Humans; Hydroxychloroqui | 2022 |
Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: a single-blind, randomized clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Brucellosis; Doxycycline; Drug Th | 2018 |
2 other studies available for hydroxychloroquine and Brucellosis
| Article | Year |
|---|---|
Use of the quantum dot-labeled solid lipid nanoparticles for delivery of streptomycin and hydroxychloroquine: A new therapeutic approach for treatment of intracellular Brucella abortus infection.
Topics: Animals; Anti-Bacterial Agents; Brucella abortus; Brucellosis; Drug Carriers; Humans; Hydroxychloroq | 2023 |
Use of the quantum dot-labeled solid lipid nanoparticles for delivery of streptomycin and hydroxychloroquine: A new therapeutic approach for treatment of intracellular Brucella abortus infection.
Topics: Animals; Anti-Bacterial Agents; Brucella abortus; Brucellosis; Drug Carriers; Humans; Hydroxychloroq | 2023 |
Use of the quantum dot-labeled solid lipid nanoparticles for delivery of streptomycin and hydroxychloroquine: A new therapeutic approach for treatment of intracellular Brucella abortus infection.
Topics: Animals; Anti-Bacterial Agents; Brucella abortus; Brucellosis; Drug Carriers; Humans; Hydroxychloroq | 2023 |
Use of the quantum dot-labeled solid lipid nanoparticles for delivery of streptomycin and hydroxychloroquine: A new therapeutic approach for treatment of intracellular Brucella abortus infection.
Topics: Animals; Anti-Bacterial Agents; Brucella abortus; Brucellosis; Drug Carriers; Humans; Hydroxychloroq | 2023 |
Co-delivery of streptomycin and hydroxychloroquine by labeled solid lipid nanoparticles to treat brucellosis: an animal study.
Topics: Animals; Animals, Laboratory; Brucellosis; Hydroxychloroquine; Mice; Nanoparticles; Rats; Streptomyc | 2023 |